PERRIGO Co plc (PRGO) stock
PRGONYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3029% below fair value
$16.24+0.06 (+0.37%)
Close on Nov 13, 2026Market cap $2.25BP/E –Yield 7.14%
Perrigo cash
Cash and short-term investments held at the end of each period.
Perrigo's cash was $436.60M at Sep 26, 2026. For fiscal 2025 it was $531.60M, down 4.9% from the year before. Over ten years it grew -4.0% a year on average. The highest annual figure on record is $1.86B in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $531.60M | -4.9% |
| FY2024 | Dec 31, 2024 | $558.80M | -25.6% |
| FY2023 | Dec 31, 2023 | $751.30M | +25.1% |
| FY2022 | Dec 31, 2022 | $600.70M | -67.8% |
| FY2021 | Dec 31, 2021 | $1.86B | +195.3% |
| FY2020 | Dec 31, 2020 | $631.50M | +83.3% |
| FY2019 | Dec 31, 2019 | $344.50M | -36.4% |
| FY2018 | Dec 31, 2018 | $541.90M | -20.2% |
| FY2017 | Dec 31, 2017 | $678.70M | -13.6% |
| FY2015 | Jun 27, 2015 | $785.60M | -1.7% |
| FY2014 | Jun 28, 2014 | $799.50M | +2.5% |
| FY2013 | Jun 29, 2013 | $779.90M | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Sep 26, 2026 | $436.60M | +1.0% |
| Q2 FY2026CQ2 2026 | Jun 27, 2026 | $399.70M | -12.0% |
| Q1 FY2026CQ1 2026 | Mar 28, 2026 | $357.20M | -12.9% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $531.60M | -4.9% |
| Q3 FY2025CQ3 2025 | Sep 27, 2025 | $432.10M | -70.5% |
| Q2 FY2025CQ2 2025 | Jun 28, 2025 | $454.20M | -16.3% |
| Q1 FY2025CQ1 2025 | Mar 29, 2025 | $409.90M | -37.8% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $558.80M | -25.6% |
| Q3 FY2024CQ3 2024 | Sep 28, 2024 | $1.46B | +144.6% |
| Q2 FY2024CQ2 2024 | Jun 29, 2024 | $542.80M | -2.2% |
| Q1 FY2024CQ1 2024 | Mar 30, 2024 | $658.50M | +19.1% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $751.30M | +25.1% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $598.30M | +27.7% |
| Q2 FY2023CQ2 2023 | Jul 1, 2023 | $555.20M | +14.4% |
| Q1 FY2023CQ1 2023 | Apr 1, 2023 | $553.00M | -71.9% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $600.70M | -67.8% |
| Q3 FY2022CQ3 2022 | Oct 1, 2022 | $468.70M | -77.4% |
| Q2 FY2022CQ2 2022 | Jul 2, 2022 | $485.30M | +52.9% |
| Q1 FY2022CQ1 2022 | Apr 2, 2022 | $1.97B | +317.4% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $1.86B | +195.3% |
| Q3 FY2021CQ3 2021 | Oct 2, 2021 | $2.08B | +147.3% |
| Q2 FY2021CQ2 2021 | Jul 3, 2021 | $317.50M | -77.9% |
| Q1 FY2021CQ1 2021 | Apr 3, 2021 | $470.90M | -4.2% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $631.50M | +83.3% |
| Q3 FY2020CQ3 2020 | Sep 26, 2020 | $840.20M | +110.8% |
| Q2 FY2020CQ2 2020 | Jun 27, 2020 | $1.44B | +36.2% |
| Q1 FY2020CQ1 2020 | Mar 28, 2020 | $491.70M | -41.3% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $344.50M | -36.4% |
| Q3 FY2019CQ3 2019 | Sep 28, 2019 | $398.50M | -10.3% |
| Q2 FY2019CQ2 2019 | Jun 29, 2019 | $1.06B | +100.5% |
| Q1 FY2019CQ1 2019 | Mar 30, 2019 | $837.90M | +21.9% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $541.90M | -20.2% |
| Q3 FY2018CQ3 2018 | Sep 29, 2018 | $444.20M | -42.8% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $526.50M | -30.8% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $687.30M | -77.7% |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | $678.70M | -13.6% |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | $775.90M | – |
| Q2 FY2017CQ2 2017 | Jul 1, 2017 | $760.80M | – |
| Q1 FY2017CQ1 2017 | Apr 1, 2017 | $3.08B | – |
| Q4 FY2015CQ2 2015 | Jun 27, 2015 | $785.60M | – |
See a number that looks wrong?